+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new drug called GSK3862995B in adults with bronchiectasis, a chronic lung disease. This Phase 2 study also examines how the body processes the drug and checks for any immune reactions. Participants will be randomly assigned to receive one of two doses of GSK3862995B or a placebo to compare their effects on bronchiectasis. Participants will receive either Dose Level 1 or Dose Level 2 of GSK3862995B, or a matching placebo. The study uses a double-blind, randomized design, meaning neither participants nor researchers know who gets which treatment. The treatment period lasts up to 48 weeks, during which participants receive repeated doses. The study also includes assessments up to 72 weeks to monitor safety and immune responses. During the trial, participants will undergo evaluations including lung function tests, quality-of-life questionnaires, and monitoring of respiratory symptoms. Researchers will track the number of lung exacerbations, serious adverse events, laboratory tests, vital signs, and electrocardiograms to assess safety and effectiveness. Participants will be involved in regular visits and assessments throughout the treatment and follow-up periods, lasting up to about 72 weeks in total.

Age: 18Years - 85YearsAll GendersPhase 2
134 locations
P

Actively Recruiting

Researchers are evaluating the effects of different doses of brivekimig compared to a placebo in adults with moderate to severe Crohns disease. This phase 2, randomized, double-blind study aims to assess the treatments impact on endoscopic response and remission. The trial includes participants who have not adequately responded to standard therapies. The study is sponsored by Sanofi and plans to enroll adults aged 18 to 75 years. Participants will be randomly assigned to receive one of two dosing regimens of brivekimig or a placebo, all administered by subcutaneous injection. The treatment period can last up to 158 weeks and includes an optional open-label long-term extension lasting up to 104 weeks for eligible participants. The study design includes three groups two experimental brivekimig dose regimens and one placebo group. Throughout the study, participants will undergo assessments to measure endoscopic response at week 16 and other clinical outcomes such as remission rates, symptom scores, serum drug levels, and safety monitoring for adverse events. Evaluations include Crohns Disease Activity Index scores, patient-reported outcomes, and endoscopic examinations up to week 52. The total duration of participation may be up to 168 weeks, with ongoing safety and efficacy monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
78 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.

Age: 40Years - 80YearsAll GendersPhase 3
193 locations
E

Actively Recruiting

Researchers are studying adults aged 18 and older who live with obesity and have a liver disease known as non-alcoholic steatohepatitis NASH or metabolic associated steatohepatitis MASH with moderate or advanced liver fibrosis. The study aims to evaluate whether a medicine called survodutide can improve liver function in people with these conditions. It is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants are randomly assigned to one of two groups one receives weekly injections of survodutide, and the other receives placebo injections that look the same but contain no medicine. The survodutide dose is gradually increased until reaching the target dose. All participants receive counseling on diet and exercise. The study includes two parts the first focuses on the effect of survodutide on NASH and fibrosis over one year, and the second assesses its long-term safety and effectiveness over up to seven years. Participants stay in the study for up to seven years, attending regular visits either in person or remotely via video call. Visits occur every two weeks initially, then every four to six weeks, and later every three months. Doctors monitor health, record any side effects, and measure body weight and digestive symptoms. Liver assessments include imaging and biopsies at selected visits. Participants also complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the medicines effects on liver health and related outcomes.

Age: 18Years +All GendersPhase 3
532 locations
P

Actively Recruiting

This research aims to compare two asthma inhalers that use different propellants in people with mild to moderate asthma. The study evaluates whether an investigational inhaler with a new climate-friendly propellant, HFA-152a, works as safely and effectively as inhalers using the existing HFA-134a propellant. This global Phase II study plans to enroll 468 patients in Europe, Latin America, Ukraine, South Africa, and the United Kingdom. Participants will use one of three inhaler treatments in a randomized, double-blind crossover design the investigational CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, or CHF718 pMDI with HFA-134a. Each inhaler is taken as two puffs twice daily. The study compares lung function effects of these inhalers during treatment periods. During the trial, participants will be assessed for lung function through measurements like forced expiratory volume in 1 second FEV1 at baseline and after treatment. Researchers will monitor safety, treatment adherence, and asthma control over the study period. Participants undergo scheduled visits for these evaluations, with the study expected to complete in June 2027.

Age: 18Years - 75YearsAll GendersPhase 2
167 locations